Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes

G. Rayman; A. N. Lumb; B. Kennon; C. Cottrell; D. Nagi; E. Page; D. Voigt; H. C. Courtney; H. Atkins; J. Platts; K. Higgins; K. Dhatariya; M. Patel; P. Narendran; P. Kar; P. Newland-Jones; R. Stewart; O. Burr; S. Thomas

doi:10.1111/dme.14378

Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes

G. Rayman (Lead / Corresponding author), A. N. Lumb, B. Kennon, C. Cottrell, D. Nagi, E. Page, D. Voigt, H. C. Courtney, H. Atkins, J. Platts, K. Higgins, K. Dhatariya, M. Patel, P. Narendran, P. Kar, P. Newland-Jones, R. Stewart, O. Burr, S. Thomas

Postgraduate Medicine

Research output: Contribution to journal › Letter › peer-review

57 Citations (Scopus)

143 Downloads (Pure)

Abstract

The RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial found that dexamethasone 6 mg once per day for 10 days reduced deaths by one-third in ventilated patients and by one-fifth in other patients, receiving oxygen therapy. This equates to the prevention of one death in around eight ventilated patients, or one in around 25 patients requiring oxygen.

Original language	English
Article number	e14378
Number of pages	5
Journal	Diabetic Medicine
Volume	38
Issue number	1
Early online date	2 Aug 2020
DOIs	https://doi.org/10.1111/dme.14378
Publication status	Published - Jan 2021

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/dme.14378

Author Accepted ManuscriptAccepted author manuscript, 3.57 MB

Cite this

Rayman, G., Lumb, A. N., Kennon, B., Cottrell, C., Nagi, D., Page, E., Voigt, D., Courtney, H. C., Atkins, H., Platts, J., Higgins, K., Dhatariya, K., Patel, M., Narendran, P., Kar, P., Newland-Jones, P., Stewart, R., Burr, O., & Thomas, S. (2021). Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes. Diabetic Medicine, 38(1), Article e14378. https://doi.org/10.1111/dme.14378

@article{a8704de959d34e8983f4c01c2c579d19,

title = "Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes",

abstract = "The RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial found that dexamethasone 6 mg once per day for 10 days reduced deaths by one-third in ventilated patients and by one-fifth in other patients, receiving oxygen therapy. This equates to the prevention of one death in around eight ventilated patients, or one in around 25 patients requiring oxygen.",

author = "G. Rayman and Lumb, {A. N.} and B. Kennon and C. Cottrell and D. Nagi and E. Page and D. Voigt and Courtney, {H. C.} and H. Atkins and J. Platts and K. Higgins and K. Dhatariya and M. Patel and P. Narendran and P. Kar and P. Newland-Jones and R. Stewart and O. Burr and S. Thomas",

year = "2021",

month = jan,

doi = "10.1111/dme.14378",

language = "English",

volume = "38",

journal = "Diabetic Medicine",

issn = "0742-3071",

publisher = "Wiley",

number = "1",

}

Rayman, G, Lumb, AN, Kennon, B, Cottrell, C, Nagi, D, Page, E, Voigt, D, Courtney, HC, Atkins, H, Platts, J, Higgins, K, Dhatariya, K, Patel, M, Narendran, P, Kar, P, Newland-Jones, P, Stewart, R, Burr, O & Thomas, S 2021, 'Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes', Diabetic Medicine, vol. 38, no. 1, e14378. https://doi.org/10.1111/dme.14378

TY - JOUR

T1 - Dexamethasone therapy in COVID-19 patients

T2 - implications and guidance for the management of blood glucose in people with and without diabetes

AU - Rayman, G.

AU - Lumb, A. N.

AU - Kennon, B.

AU - Cottrell, C.

AU - Nagi, D.

AU - Page, E.

AU - Voigt, D.

AU - Courtney, H. C.

AU - Atkins, H.

AU - Platts, J.

AU - Higgins, K.

AU - Dhatariya, K.

AU - Patel, M.

AU - Narendran, P.

AU - Kar, P.

AU - Newland-Jones, P.

AU - Stewart, R.

AU - Burr, O.

AU - Thomas, S.

PY - 2021/1

Y1 - 2021/1

N2 - The RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial found that dexamethasone 6 mg once per day for 10 days reduced deaths by one-third in ventilated patients and by one-fifth in other patients, receiving oxygen therapy. This equates to the prevention of one death in around eight ventilated patients, or one in around 25 patients requiring oxygen.

AB - The RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial found that dexamethasone 6 mg once per day for 10 days reduced deaths by one-third in ventilated patients and by one-fifth in other patients, receiving oxygen therapy. This equates to the prevention of one death in around eight ventilated patients, or one in around 25 patients requiring oxygen.

UR - http://www.scopus.com/inward/record.url?scp=85090945578&partnerID=8YFLogxK

U2 - 10.1111/dme.14378

DO - 10.1111/dme.14378

M3 - Letter

C2 - 32740972

SN - 0742-3071

VL - 38

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 1

M1 - e14378

ER -

Dexamethasone therapy in COVID-19 patients: implications and guidance for the management of blood glucose in people with and without diabetes

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this